We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go: Stretch investment: Withheld
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
Leaseum is a Business to Business (B2B) Software as a Service (SaaS) provider based in London that offers white label capital raising portals to its clients and targets alternative investment managers who deal with private equity, venture capital, real estate, hedge funds and private credit. The company claims that fundraising for alternative investments is time consuming, expensive and involves many compliance and regulatory aspects. It aims to change this by bringing together all the tools needed to raise capital such as an investor portal, a Customer Relationship Management (CRM) system, an email marketing module, e-signature facility, and investor onboarding compliances. Leaseum claims that it allows its clients to streamline their fundraising processes and convert more leads into investors via its portal. It will use 40% of the investment to strengthen its sales team, 40% to strengthen its IT team, and 20% for marketing.
days to go: Expired investment: £76,440
Gridizen desires to change the way agencies and landlords manage their properties whilst enhancing the tenant experience. It eliminates manual methods and gives landlords and tenants a way to manage and communicate their rental property. Further, its central management team has a number of relationships within the market to build up the customer base and create a buzz about the product which other companies lack. Gridizen aspires to be the property management solution of choice for tenants and landlords. With the proceeds, it will fully develop the Property Management module, recruit an in-house technical team to oversee the development and recruit sales and marketing support.
days to go: Expired investment: £150,004
ReCircle Recycling has designed an appliance meant for installation in households, businesses and new developments to grind glass bottles, compact metal cans, and flake plastic packaging straight into ready to use manufacturing material. This process allows Recircle Recycling to set up a new closed-loop system where packaging is endlessly recycled. It increases the purity and value of all the materials. When manufacturers finally have access to high-grade recycled to minimise their carbon footprints and where consumers and businesses receive payback for the true value of their recycled product. ReCircle collects and delivers materials from a common man's curb 3-8 times a year. It has established strong connections and technology developments with the UK University. ReCircle has also filed patents with the USA, Japan, China, Europe, and India. ReCircle is also building a close relationship with Swansea University. It intends to launch in California, which has the highest recycling rate in the US.
days to go: Expired investment: £548,150
DNApal is a personalised diet, health and fitness app that combines DNA infomation with other factors like age, weight, diet, family history and health goals. Two of the largest consumer DNA companies, 23andMe and Ancestry.com, have tested over 18m people. DNApal is capable of interpreting DNA results from these companies to provide precise recommendations on how to improve diet, hormone balance, weight loss, sleep, fitness & more. The company also won the best pitch at VentureFest 2019 at Oxford Brookes University. DNApal is aiming to launch MVP in January 2020 (iOS). The company is also aiming to recommend further testing and specific supplements where necessary and offer 1:1 consultations with a specialist. With the fund raised, DNApal plans to develop the full scope of the app, weekly goals, content challenges to keep users committed.

Pitch Rated

70%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £49,990
Nutrifix is an app that locates healthy meals nearby or selects recipes or delivery options all tailored to you bodies needs. The app is like having a personal nutritionist in your pocket and is in a growing sector as the global value of mobile health solutions is set to reach 83,000,000,000 by 2022.

Pitch Rated

70%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £194,310
Actve is on a mission to change the way people connect with their favourite fitness creators. The company aspires to help creators earn an income and build a subscription business. Actve asserts that it caters to a variety of creator needs allowing them to live-stream their workouts, offer guided programs to customers, or use Actve's software to manage their clients. The company aims to become a contender in the digital fitness market that is projected to be worth £21 billion by 2022. It aims to launch its platform in September 2021. Actve will use the investment to develop its platform, hire key staff, build its user base, and work towards becoming an industry champion for fitness creators.
days to go: Expired investment: £165,627
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph